A Somerset woman says she suffered a severe asthma attack after having her prescription changed without consultation. Sue* has lived with asthma for 42 years and is used to using a blue inhaler. But ...

Eli Lilly LLY0.80%increase; green up pointing triangle received approval from the Food and Drug Administration for a label expansion of its weight-loss drug Zepbound, adding a new monthly delivery ...

Please provide your email address to receive an email when new articles are posted on . A revised technosphere insulin label recommends patients start using the therapy at a higher dose than ...

New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. Earlier this year, my wife and I welcomed our son ...

• Skipping antibiotic doses can lower drug levels and reduce effectiveness. • Missing doses—especially multiple—can slow recovery and raise antibiotic resistance risk. • Don’t double doses; take a ...

An initial dose of 0.3 mg intramuscular (IM) epinephrine was tied to a greater escalation of care than a dose of 0.5 mg in patients with anaphylaxis, a retrospective single-center study found. The ...

Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Many drugs in development continue to follow the historical drug development ...

In Janssen Pharmaceuticals, Inc. v. Mylan Laboratories., the United States Court of Appeals for the Federal Circuit affirmed a district court ruling that a pharmaceutical dosing claim limitation was ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses.

The MUSETTE trial found no additional benefit in higher doses of ocrelizumab for RMS compared to the standard 600 mg dose. The 600 mg dose of ocrelizumab remains optimal for slowing disability ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...